Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia

Pinkhas Sirota, Tanya Mosheva, Hertzel Shabtay, Nir Giladi, Amos D. Korczyn

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: The authors examined the efficacy, tolerability, and safety of ondansetron, a selective serotonin 3 receptor antagonist, in patients with tardive dyskinesia. Method: Twenty patients with schizophrenia who had neuroleptic-induced tardive dyskinesia were given 12 mg/day of ondansetron for 12 weeks in an open-label study. Results: Administration of ondansetron resulted in a statistically significant improvement in tardive dyskinesia and psychotic symptoms. Conclusions: Ondansetron may be an effective and safe therapy to control tardive dyskinesia and psychosis in patients with schizophrenia.

Original languageEnglish
Pages (from-to)287-289
Number of pages3
JournalAmerican Journal of Psychiatry
Volume157
Issue number2
DOIs
StatePublished - Feb 2000

Fingerprint

Dive into the research topics of 'Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia'. Together they form a unique fingerprint.

Cite this